Bedside to Bench: Interrogating Preclinical Models for Precision Oncology
Time: 10:30 am
day: Conference Day 2
Details:
- Exploring how precision oncology customises cancer treatment based on the genetic and molecular profiles of patients’ tumours
- Utilising mono- and co-culture patient-derived organoids (PDOs) and xenografts to help identify biomarkers for optimising regorafenib treatment in metastatic colorectal cancer
- Using paired tissue and liquid biopsies from a phase II trial, identified MIR652-3p as a biomarker and molecular driver of resistance to regorafenib
